A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzony nowotwór płuca (niedrobnokomórkowy)
- •Co najmniej jeden widoczny guz do zmierzenia
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Przewidywana długość życia co najmniej 12 tygodni
- •Prawidłowe funkcjonowanie narządów wewnętrznych i szpiku kostnego
- •Dobrowolna zgoda na udział i możliwość uczestniczenia we wszystkich wizytach
✗ Disqualifies
- •Inny nowotwór w ostatnich 3 latach
- •Przerzuty do mózgu (aktywne lub nieleczone)
- •Niekontrolowane choroby współistniejące
- •Poważne uszkodzenie płuc z powodu powikłań
- •Historia zapalenia płuc lub choroby zmiany śródmiąższowej
- •Historia poważnych chorób skóry
- •Ciężka infekcja w ostatnich 4 tygodniach
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (27)
Peking University Cancer Hospital
Beijing, China
Xinqiao Hospital of Army Medical University
Chongqing, China
Fujian Provincial Cancer Hospital
Fuzhou, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Dongguan People's Hospital
Dongguan, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Guangzhou Medical University First Affiliated Hospital
Guangzhou, China
Guilin Medical University First Affiliated Hospital
Guilin, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, China
Harbin Medical University Cancer Hospital
Harbin, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Xiangyang Central Hospital
Xiangyang, China
Hunan Cancer Hospital
Changsha, China
Jiangsu Province Hospital
Nanjing, China
Jiangxi Cancer Hospital
Nanchang, China
Jilin Cancer Hospital
Changchun, China
Shengjing Hospital of China Medical University
Shenyang, China
Shandong Cancer Hospital
Jinan, China
Shanxi Cancer Hospital
Taiyuan, China
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, China
Sichuan Cancer Hospital & Institute
Chengdu, China
West China Hospital, Sichuan University
Chengdu, China
Tianjin Cancer Hospital
Tianjin, China
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, China
Yunnan Cancer Hospital
Kunming, China
Zhejiang Cancer Hospital
Hangzhou, China
Trial contact
Xin Li, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.